Login to Your Account



HGS' Phase II Data Mixed; Lupus Effort Moves Ahead

By Randall Osborne


Thursday, October 6, 2005
Mixed news from a Phase II study testing its lupus drug sent shares of Human Genome Sciences Inc. into a tailspin, but the company plans to push ahead with development based on a clearly identified target patient group and a dose that works for it. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription